Based on their tumour PD-L1 expression, patients receive either pembrolizumab monotherapy (PD-L1 expression ≥50%) or pembrolizumab in combination with platinum-based doublet chemotherapy (PD-L1 expression <50%) (Reck et al., 2019; Gadgeel et al., 2020). The gene discussed is CD274; the disease is neoplasm.